ReutersCodex · 实盘不做把握 8/10
北京时间·🕒 发布 07-16 23:55:50时区推断·⟳ 抓取 01:35:17·⚡ 决策 07-17 02:03:53 +28m36s·102.8 天前
印度Serum将与Gates MRI合作生产试验性结核疫苗，GSK供应AS01E佐剂
M72/AS01E仍处后期临床试验，Serum计划投入超过1亿美元扩产取决于未来获批，不是GSK当前确认收入订单。
📄 原文Reuters↗ 原文
Serum Institute of India said on Thursday it would manufacture an experimental tuberculosis vaccine under an agreement…
不做 GSK（GSK.GB）
长期利好期权但不是已获批产品或确定订单，且未披露GSK销售额、分成或利润量级；对GSK短线市值影响不足，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-16 · 扩散 medium · price-in 风险 medium ↗
关键理由
- M72/AS01E仍处后期临床试验，Serum计划投入超过1亿美元扩产取决于未来获批，不是GSK当前确认收入订单。
- GSK角色是供应AS01E佐剂且此前已将候选疫苗授权给Gates MRI，经济权益和商业化分成未在报道中披露。
- 量级上，WHO估计25年可避免7600万新病例和节省415亿美元是公共卫生潜力，不等同于GSK可确认销售或利润。
主要风险
- 若疫苗获批且GSK佐剂供货条款优厚，长期有上行期权；但当前缺少批准、定价、采购量和GSK权益比例。
原文全文
展开原文 · 1,907 字
Serum Institute of India said on Thursday it would manufacture an experimental tuberculosis vaccine under an agreement with the Gates Medical Research Institute, in what is likely to be the first new TB shot in more than 100 years if approved.
The novel vaccine candidate, M72/AS01E, has been in development for two decades and is currently in a late-stage clinical trial.
Serum Institute plans to invest more than $100 million to scale up manufacturing capacity and prepare for future vaccine supply, pending approval, the company said.
Under the agreement, Gates MRI, founded by the Gates Foundation, will transfer the technology and know-how needed to manufacture the vaccine antigen and enable large-scale production, Serum Institute said.
GSK (GSK.L) , which originally developed the vaccine candidate, will supply the AS01E adjuvant, an ingredient used to boost the body's immune response.
GSK advanced the vaccine through mid-stage testing before licensing it to Gates MRI, which is sponsoring the late-stage trial with support from the Gates Foundation and Wellcome, a major London-based charity.
Tuberculosis is the world's leading cause of death from a single infectious agent and is among the top 10 causes of death, the WHO said in a report last year.
Nearly 11 million people contracted tuberculosis in 2024, while 1.23 million died from the disease, according to the WHO's data.
India, Indonesia, the Philippines, China, Pakistan and Nigeria are among the countries bearing the highest burden of tuberculosis, the WHO said.
"The World Health Organization estimates a vaccine with this efficacy profile could prevent 76 million new TB cases, save 8.5 million lives, and save $41.5 billion for TB-affected households over 25 years," Serum and Gates MRI said.
The Bacille Calmette-Guérin (BCG) vaccine is currently the only widely used vaccine against tuberculosis.
The novel vaccine candidate, M72/AS01E, has been in development for two decades and is currently in a late-stage clinical trial.
Serum Institute plans to invest more than $100 million to scale up manufacturing capacity and prepare for future vaccine supply, pending approval, the company said.
Under the agreement, Gates MRI, founded by the Gates Foundation, will transfer the technology and know-how needed to manufacture the vaccine antigen and enable large-scale production, Serum Institute said.
GSK (GSK.L) , which originally developed the vaccine candidate, will supply the AS01E adjuvant, an ingredient used to boost the body's immune response.
GSK advanced the vaccine through mid-stage testing before licensing it to Gates MRI, which is sponsoring the late-stage trial with support from the Gates Foundation and Wellcome, a major London-based charity.
Tuberculosis is the world's leading cause of death from a single infectious agent and is among the top 10 causes of death, the WHO said in a report last year.
Nearly 11 million people contracted tuberculosis in 2024, while 1.23 million died from the disease, according to the WHO's data.
India, Indonesia, the Philippines, China, Pakistan and Nigeria are among the countries bearing the highest burden of tuberculosis, the WHO said.
"The World Health Organization estimates a vaccine with this efficacy profile could prevent 76 million new TB cases, save 8.5 million lives, and save $41.5 billion for TB-affected households over 25 years," Serum and Gates MRI said.
The Bacille Calmette-Guérin (BCG) vaccine is currently the only widely used vaccine against tuberculosis.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。